Healthcare Web Wire

Author: Elena Morales

Automated Sample Storage Systems Market Growth, Trends and Future Outlook
Automated Sample Storage Systems Market Overview: Growth, Trends, and Analysis

The global market for automated sample storage systems is valued at USD 1.28 billion in 2024 and is expected to grow to USD 1.42 billion in 2025. By 2034, the market is projected to reach approximately USD 3.71 billion, reflecting a compound annual growth rate (CAGR) of 11.24% from 2024 to 2034. This growth is driven by technological innovations, a surge in research and development activities, and increased investments in the sector.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5370

The Future of Automated Sample Storage Systems: Key Trends and Insights

Automated sample storage systems are revolutionizing the way biological and compounded samples are stored by utilizing advanced computerized technologies. These systems are designed to store samples at ultra-low temperatures and enable automatic retrieval or discharge of samples according to programmable schedules. By ensuring sample integrity during both short- and long-term storage, they provide flexibility and reliability. This automation allows researchers to focus more on their work, enhancing productivity and reducing the time spent on managing samples.

The rise in demand for automation in industries like pharmaceuticals and biotechnology, driven by technological advancements, is fueling the growth of the automated sample storage systems market. The expanding life sciences sector and increased investments are also playing key roles. Additionally, the demand for efficient storage solutions is growing due to increasing research and development (R&D) activities, including drug discovery, and the need to store complex samples. The rising number of biobanks is further boosting the market.

Key Trends in the Market
- Strategic Partnerships: In May 2023, Health Services Laboratories (HSL) partnered with Automata Technologies to enhance turnaround times for pathology and diagnostic services by developing an automated system for sample storage.
- Technological Advancements: In January 2022, Hamilton Company expanded its Verso Q-Series with new models like the Verso Q50 and Verso Q75, offering compact, automated storage solutions to reduce manual labor and improve efficiency.
- Strong Market Performance: Azenta Life Sciences reported a 25% year-over-year revenue increase in Q4 2023, driven by their offerings in genomics, cryogenic storage, and automation.
The Role of AI in Automated Sample Storage

Artificial intelligence (AI) is transforming laboratory operations by enabling automation in sample storage systems. AI helps improve research efficiency by integrating advanced features like RFID technology for faster and more reliable sample identification and real-time tracking. Additionally, AI-driven predictive analytics powered by machine learning (ML) can forecast potential issues, identify trends, and optimize storage operations, resulting in better performance and resource utilization while reducing administrative overhead.

Market Dynamics
- Driver: Growing Research and Development
  Research activities in the pharmaceutical, biotechnology, and life sciences sectors, especially around drug discovery and genomics, are driving the demand for automated sample storage systems. The growing number of clinical trials and the need for efficient storage and tracking of large sample volumes further contribute to the market’s growth.
- Restraint: High Installation Costs and Skill Shortage
  The high initial investment required for automated systems remains a significant barrier, especially in low- and middle-income countries. Additionally, the lack of trained professionals to operate these systems is another challenge limiting market growth.
- Opportunity: Increasing Demand for Biobanking
  The rising prevalence of chronic diseases and growing awareness about blood donations are increasing the demand for biobanks. These biorepositories store biological samples for research purposes, with AI playing a significant role in enhancing their efficiency. Investments in biobank networking are helping connect multiple sites, enabling resource sharing and improving sample storage.
Regional Insights
- North America Leads the Market
  North America holds the largest share of the automated sample storage systems market, thanks to a strong presence of key players, advanced R&D activities, and favorable government policies. The U.S. government supports the use of automated systems in biobanks and research institutions, which further drives market growth.
- Asia-Pacific: Fastest Growing Region
  The Asia-Pacific region is expected to see the fastest growth in the market, driven by increasing research activities and technological advancements. Countries like India and China are witnessing growing R&D in drug discovery and precision medicine, boosting the demand for automated sample storage solutions.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/automated-sample-storage-systems-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5370

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
December 17, 2024
Glycomics Market Growth, Trends and Key Insights (2024 – 2034)
Glycomics Market Overview Size, Growth and Key Developments

The global glycomics market is poised for significant growth, with its value estimated at USD 2.21 billion in 2024 and expected to rise to USD 2.53 billion by 2025. Over the next decade, the market is projected to reach approximately USD 8.66 billion by 2034, advancing at a robust CAGR of 14.64% from 2024 to 2034.

This growth is driven by the increasing applications of glycomics in critical areas such as drug discovery, disease diagnostics, therapeutics, and personalized medicine. The field’s ability to enhance understanding of glycan structures and their role in biological processes is fueling demand for glycomics tools and technologies.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5371

Glycomics Market Overview

Glycomics studies the complex sugars (glycans) in biological systems and their roles in various biological processes. The field has advanced significantly due to new analytical tools, especially in areas like drug discovery, disease diagnosis, and personalized medicine.

Key Market Trends
- Research Investments: In May 2024, Genome Canada invested in genomics infrastructure, enhancing glycomics research through Alberta’s Metabolomics Innovation Centre and GlycoNet Integrated Services.
- Glycan Biomarker Advances: In February 2024, GlycanAge, a biotech firm, raised €3.9 million to focus on personalized healthcare using glycan biomarkers.
- AI Integration: AI is still in early stages in glycomics but shows potential in predicting glycan behaviors and enhancing disease diagnostics and treatments.
Market Dynamics
- Driver: Glycans play a critical role in precision medicine, influencing how individuals respond to treatments.
- Restraint: The complexity of glycan analysis remains a challenge due to the need for specialized techniques.
- Opportunity: Recombinant glycans are becoming easier to synthesize, expanding research possibilities.
Segment Insights
- Enzymes dominate the market and are expected to grow rapidly.
- Drug Discovery holds the largest share, with glycomics offering tools for better drug design and efficacy.
- Diagnostics is the fastest-growing segment, driven by the discovery of new glycan biomarkers.
- Academic Institutes lead in end-use, supporting key research, while biopharmaceutical companies are set for the fastest growth due to glycomics’ role in developing therapeutic agents.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/glycomics-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5371

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
December 17, 2024
Resorbable Nerve Conduits Market Pioneering Growth in Peripheral Nerve Repair Solutions
Growing Demand for Resorbable Nerve Conduits Market Trends and Regional Insights

The global market for resorbable nerve conduits was valued at US$ 2.31 billion in 2023 and is expected to reach US$ 5.28 billion by 2034, growing at a CAGR of 7.8% from 2024 to 2034. This growth is driven by the increasing need for effective nerve injury treatments that minimize inflammation while promoting natural nerve regeneration, enhancing the adoption of resorbable nerve conduits worldwide.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5319

Market Overview

Resorbable nerve conduit devices are made from either natural or synthetic materials. For instance, the use of a resorbable polyglycolic acid (PGA) tube filled with collagen sponge has been shown to effectively restore both sensory and motor electrophysiological functions. This approach is considered more advanced compared to traditional autograft techniques.

Combining resorbable synthetic tubes with biological factors is paving the way for future advancements by accelerating and supporting nerve regeneration. The integration of neurotrophic factors has proven successful in promoting axonal growth in in vitro studies; however, their application in in vivo settings remains largely unexplored.

Resorbable Nerve Conduits Market Trends

Overview

The global resorbable nerve conduits market is experiencing significant growth due to increasing incidences of nerve injuries, advancements in regenerative medicine, and the rising adoption of bioresorbable materials. Resorbable nerve conduits, also known as biodegradable nerve conduits, offer a non-permanent solution to aid peripheral nerve repair by facilitating regeneration without requiring secondary removal surgeries.

Key Market Drivers
- Rising Incidence of Nerve Injuries: Increasing road accidents, trauma cases, and sports-related injuries are driving the need for advanced solutions in nerve repair.
- Technological Advancements: Innovations in materials, such as polyglycolic acid (PGA) and polycaprolactone (PCL), are enhancing conduit performance and biocompatibility.
- Surge in Regenerative Medicine: Growing focus on regenerative therapies to restore damaged nerves is propelling demand for resorbable conduits.
- Minimally Invasive Techniques: Adoption of advanced surgical methods to repair peripheral nerves is accelerating market growth.
Emerging Trends
- Development of Novel Biodegradable Materials: Companies are investing in advanced polymers and natural materials (e.g., collagen) to create conduits with better flexibility, durability, and nerve regeneration efficiency.
- Increasing Use of 3D Printing: 3D printing technology is being leveraged to create customized resorbable conduits tailored to patient-specific needs.
- Combination with Growth Factors: Integration of nerve growth factors (NGFs) into conduits is enhancing the success rate of nerve regeneration.
- Focus on Biodegradability and Sustainability: Preference for eco-friendly and non-toxic materials is influencing product design.
Challenges
- High Cost of Treatment: The use of resorbable nerve conduits can be costly, limiting adoption in low-resource settings.
- Limited Clinical Evidence: Although promising, long-term clinical data supporting their efficacy compared to autografts is still evolving.
- Regulatory Hurdles: Stringent regulatory approval processes for new biodegradable materials can delay market entry.
Market Opportunities
- Rising Healthcare Expenditure: Increasing investments in healthcare infrastructure and research are creating favorable conditions for market expansion.
- Growing Focus on Emerging Markets: Developing regions, such as Asia-Pacific and Latin America, offer untapped potential due to improving healthcare systems.
- Strategic Collaborations: Partnerships among biotech firms, research institutions, and manufacturers are accelerating innovation and product development.
Leading Companies

Key players in the resorbable nerve conduits market include:
- Axogen, Inc.
- Collagen Matrix, Inc.
- Integra LifeSciences Corporation
- Polyganics BV
- Stryker Corporation
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/resorbable-nerve-conduits-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5319

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
December 17, 2024
Single-use Pump Market Size, Trends and Future Growth Analysis
Single-use Pump Market Overview

The global single-use pump market, valued at US$ 451.81 million in 2023, is expected to reach US$ 2,133.2 million by 2034, growing at a CAGR of 15.95%. Rising adoption in biopharmaceuticals drives this growth, as single-use pumps reduce cleaning costs and prevent cross-contamination, ensuring product purity and sterility.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5372

Market Overview

The single-use pump market is experiencing significant growth due to its numerous advantages, including reduced sterilization and cleaning costs, contamination prevention, easy component replacement, and faster operation. These pumps are designed to meet various application needs, offering consistency, accuracy, low energy consumption, and reliable performance in biopharmaceutical production. A key feature of single-use pumps is their ability to eliminate the high costs and downtime associated with cleaning and maintenance, making them ideal for large-scale processes like handling, transferring, and purifying biologic drugs produced from cell cultures and microorganisms.

For example:
- In February 2022, Colly Flowtech’s Ultrapure business area experienced strong demand for single-use products in the life sciences, pharmaceutical, and biotech sectors, offering flexibility and faster prototyping capabilities.
Growth of the Single-Use Pump Market in Pharma and Biotech Industries

The pharmaceutical and biotechnology industries are increasingly adopting single-use pump technology to streamline manufacturing processes and reduce costs. These pumps eliminate the need for cleaning, sterilization, and downtime, enabling faster drug development while ensuring product purity and sterility. Single-use technology is particularly beneficial for bioderived medicines, as it prevents contamination and improves operational efficiency.

For example:
- In November 2023, PSG Biotech, a division of Dover, launched the Quattroflow QB2 Standard (QB2-SD) single-use precision micro pump to enhance efficiency in pharmaceutical processes.
Market Trends

Single-use technologies are revolutionizing fluid-handling systems, improving production efficiency and vaccine quality. Key trends driving the market include:
- Automatic Pump Controllers: These systems reduce manual intervention by interacting with pressure and flow sensors to automatically adjust parameters, enhancing pump performance and operational consistency.
- Waste Reduction and Profitability: Single-use systems help manufacturers optimize waste disposal and boost profitability, further driving market adoption.
For instance:
- In April 2024, advancements in single-use pumping systems highlighted their flexibility in changing flow and pump sizes, accelerating market growth.
AI Integration in the Single-Use Pump Market

Automation and artificial intelligence (AI) are playing a pivotal role in advancing single-use pump systems. AI-driven automation improves productivity by optimizing pump operations, predicting performance, and minimizing errors. These next-generation systems enable faster, smarter decision-making, driving efficiency and value for manufacturers.

For example:
- In October 2024, ConnectM Technology Solutions received the prestigious AHRI cold climate certification, marking a milestone in energy-efficient solutions.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/single-use-pump-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5372

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
December 17, 2024
Induced Pluripotent Stem Cells Market Key Companies and Insights
Induced Pluripotent Stem Cells Market Size, Companies and Developments

The global induced pluripotent stem cells market is valued at USD 1.93 billion in 2024, with growth expected to reach USD 2.13 billion in 2025. The market is projected to surge to approximately USD 5.12 billion by 2034, expanding at a compound annual growth rate (CAGR) of 10.25% from 2024 to 2034. Key drivers of this growth include the increasing prevalence of chronic diseases, rising demand for regenerative medicine, and significant advancements in related technologies.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5373

Top Companies in the Induced Pluripotent Stem Cells Market
1. Accelerated Biosciences
  Accelerated Biosciences specializes in the development of cutting-edge iPSC-derived cell therapies. The company is focused on advancing regenerative medicine using induced pluripotent stem cells to treat a range of chronic and degenerative diseases.
2. Aspen Neuroscience, Inc.
  Aspen Neuroscience is committed to pioneering the use of iPSCs in the field of neurodegenerative diseases. The company’s approach involves generating personalized neuronal cells from iPSCs to develop targeted therapies for conditions such as Parkinson’s disease.
3. Axol Bioscience
  Axol Bioscience provides iPSC-derived cell lines and related services for drug discovery and regenerative medicine. The company’s products enable research into disease modeling, cell therapy, and drug screening.
4. Cynata Therapeutics
  Cynata Therapeutics is a leading biopharmaceutical company that leverages its proprietary Cymerus™ stem cell platform to develop therapeutic products derived from iPSCs. Their focus is on advancing regenerative therapies for a variety of conditions, including cardiovascular diseases.
5. Evotec
  Evotec is a global leader in providing innovative solutions in the field of cell-based assays and regenerative medicine. The company partners with research institutions to explore the potential of iPSCs for drug development and cell therapy applications.
6. Fujifilm
  Fujifilm plays a key role in the induced pluripotent stem cell market through its advancements in stem cell culture media, cell banking, and drug discovery platforms. Their technologies are widely used in regenerative medicine and cell-based therapies.
7. Healios
  Healios is focused on the development of iPSC-derived therapies for the treatment of ocular diseases, such as age-related macular degeneration. The company is advancing innovative treatments based on stem cell technology.
8. Ncardia
  Ncardia specializes in iPSC-derived cardiomyocytes, providing advanced models for drug discovery and testing. Their platforms are utilized to explore heart-related diseases and develop new therapeutic solutions.
9. NEXEL
  NEXEL is a biotechnology company working on iPSC-based solutions for the treatment of various diseases, particularly those involving tissue repair and regeneration. The company’s focus is on creating sustainable and scalable stem cell technologies.
10. Pluristyx
  Pluristyx provides expertise in iPSC technology for cell and gene therapy applications. The company works with partners to optimize stem cell culture, differentiation, and manufacturing processes for clinical use.
11. Semma Therapeutics
  Semma Therapeutics is dedicated to developing iPSC-based therapies for diabetes and other metabolic disorders. Their innovative approach involves creating insulin-producing cells derived from iPSCs for potential clinical treatments.
12. Stemson Therapeutics
  Stemson Therapeutics is focused on creating stem cell-based treatments for hair loss. Using iPSCs, the company aims to regenerate hair follicles and provide lasting solutions for conditions such as androgenic alopecia.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/induced-pluripotent-stem-cells-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5373

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
December 16, 2024
Plasma Fraction Market Key Players and Growth Insights
Plasma Fraction Market Size, Trends and Regional Growth

The global plasma fraction market was valued at US$ 32.75 billion in 2023 and is expected to reach US$ 72.86 billion by 2034, growing at a compound annual growth rate (CAGR) of 7.54% from 2024 to 2034. The increasing demand for plasma-derived medicines to treat conditions such as rabies, tetanus, shock, and trauma is a key factor driving the growth of the plasma fraction market.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5304
Top Companies in the Plasma Fraction Market

Baxter International
Baxter International is a global healthcare company that specializes in the development and production of plasma-based therapies, including treatments for hemophilia, immune deficiencies, and other conditions requiring plasma-derived therapies. Their products are sold worldwide, catering to diverse medical needs.

Bayer
Bayer is a multinational pharmaceutical and life sciences company that produces plasma-derived products as part of its extensive healthcare portfolio. Bayer’s offerings focus on treating rare diseases and chronic conditions using plasma fractionation technology.

Biotest
Biotest is a global biotech company focused on the development, production, and commercialization of plasma-based therapeutics. It specializes in immunology, hematology, and intensive care medicine, offering a wide range of plasma-derived products.

BPL (Bio Products Laboratory)
BPL is a leading provider of plasma-derived therapies, specializing in the treatment of rare and chronic diseases, including hemophilia and immune deficiencies. The company is renowned for its commitment to high-quality products and innovation in the plasma fraction market.

CBPO (China Biologic Products, Inc.)
CBPO is a major player in the plasma fraction market, known for its production of high-quality human plasma-derived products. It provides treatments for immune deficiencies, bleeding disorders, and other therapeutic areas in China and globally.

CSL Behring
CSL Behring, a division of CSL Limited, is a global leader in the development and production of human plasma-based therapies. The company focuses on a range of conditions such as hemophilia, immune deficiencies, and bleeding disorders, providing life-saving treatments worldwide.

Fusion Healthcare
Fusion Healthcare develops and manufactures plasma-derived therapies, focusing on providing advanced medical treatments to address immunological and hematological disorders. The company is known for its high-quality products and global reach.

Grifols
Grifols is a Spanish multinational corporation that specializes in the development of plasma-derived medicines. It is one of the largest players in the plasma fraction market, offering therapies for diseases such as hemophilia, immune deficiencies, and other chronic conditions.

Kedrion Biopharma Inc.
Kedrion Biopharma is a global biopharmaceutical company that focuses on the development, production, and distribution of plasma-derived therapies. Their product portfolio includes treatments for bleeding disorders and immune deficiencies, contributing to the advancement of plasma fractionation.

KM Biologics
KM Biologics, part of the Japan-based KM Group, focuses on producing plasma-derived medicines, including immunoglobulins and coagulation factors. The company is dedicated to expanding its presence in the global plasma fraction market.

LBF USA
LBF USA is a key player in the plasma fraction market, specializing in the development and distribution of plasma-derived products. Their offerings are critical for the treatment of a wide range of diseases, especially those related to immune and bleeding disorders.

LFB Group
LFB Group is a French biotechnology company that develops and manufactures plasma-derived therapeutics. The company’s products treat various health conditions, including hemophilia, immune deficiencies, and other serious illnesses.

Nanyue Bio
Nanyue Bio is a leading Chinese biopharmaceutical company that focuses on the production of plasma-derived products. Their range of therapies addresses conditions such as immune deficiencies and bleeding disorders, contributing to the advancement of the global plasma fraction market.

Octopharma
Octopharma is a Swiss-based company specializing in the development of human plasma-derived therapies. Their product range includes immunoglobulins, clotting factors, and albumin, offering life-saving treatments for a variety of diseases worldwide.

RAAS (Rafael Advanced Defense Systems)
RAAS is involved in the plasma fraction market with a focus on producing high-quality plasma-derived treatments. Their products are essential for treating chronic and rare diseases, especially those related to bleeding and immune deficiencies.

Takeda Pharmaceuticals
Takeda Pharmaceuticals is a global biopharmaceutical company that produces a broad range of plasma-derived therapies. The company’s portfolio includes treatments for hemophilia, immune system disorders, and other plasma-related diseases, expanding its footprint in the global market.

Tiantan Bio
Tiantan Bio is a Chinese biopharmaceutical company known for producing plasma-derived products for the treatment of chronic diseases. The company is expanding its global presence with a focus on quality and innovation in plasma fractionation.

Weiguang Bio
Weiguang Bio is a Chinese biotechnology company that focuses on plasma fractionation and the development of plasma-derived therapies. Their products serve critical therapeutic needs in immunology and hematology, playing a significant role in the plasma fraction market.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/plasma-fraction-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5304

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
December 16, 2024
Sterile Disposable Vacuum Blood Collection Tube Market Trends, Growth Drivers and Future Outlook
Growth and Trends in the Sterile Disposable Vacuum Blood Collection Tube Market

The sterile disposable vacuum blood collection tube market was valued at US$ 2.63 billion in 2023 and is forecasted to reach US$ 5.84 billion by 2034, expanding at a compound annual growth rate (CAGR) of 7.53% between 2024 and 2034. This growth is primarily driven by the increasing demand for biochemical and immunological tests, alongside the rising prevalence of chronic diseases.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5321

Sterile Disposable Vacuum Blood Collection Tube Market Overview

Sterile disposable vacuum blood collection tubes are sealed containers used for collecting blood samples from patients. These tubes, typically made from glass or plastic, feature a color-coded rubber stopper on one end and a needle on the other. Designed for single use, they are discarded after use to maintain sterility and prevent contamination. Depending on the test to be conducted, these tubes may contain additives such as anticoagulants, clot activators, or preservatives, with the stopper color indicating the specific additive.

The demand for blood collection tubes is growing due to the rising number of laboratory tests, including biochemical, immunological, diabetes, and tuberculosis diagnostics. Increasing awareness of the importance of preventing cross-contamination, along with expanding healthcare infrastructure, is further fueling market growth. Government policies promoting healthcare advancements and the rising need for regular lab tests to detect and monitor chronic conditions also contribute to the growing demand for sterile, disposable blood collection tubes.

Sterile Disposable Vacuum Blood Collection Tube Market Trends
- In October 2023, an Iranian company introduced a fully automatic vacuum blood collection test tube production line capable of manufacturing 60 million tubes per year. This automated line utilizes ultrasonic nozzles for enhanced production efficiency.
- In May 2023, CML Biotech, a leading Indian manufacturer of blood collection tubes, installed the world’s first integrated machine, “HUSKY-ICHOR,” by Husky Technologies. This Rs 12 crore investment can produce 800,000 blood collection tubes daily.
- Greiner Bio-One, a global leader in biotechnology and medical diagnostics, reported sales revenue of 637 million euros in 2023.
Sterile Disposable Vacuum Blood Collection Tube Market Growth Drivers
- Increasing Laboratory Tests: The rising number of biological and immunological laboratory tests drives the demand for sterile disposable vacuum blood collection tubes.
- Expanding Healthcare Expenditure: Growing healthcare investments and infrastructure support market expansion.
- Rising Prevalence of Chronic Disorders: The increasing incidence of chronic conditions such as diabetes, cholesterol, thyroid, and hematological disorders demands regular blood tests, further boosting the market.
Role of AI in the Sterile Disposable Vacuum Blood Collection Tube Market

Artificial intelligence (AI) has vast potential in healthcare, and while its application in the sterile disposable vacuum blood collection tube sector is still emerging, it promises to enhance manufacturing and diagnostic processes. AI can introduce automation into production, improving efficiency, accuracy, and consistency while reducing human error. Additionally, AI can help in error detection during diagnosis and blood collection, offering real-time data on the volume of blood collected per patient. This integration of AI presents significant growth opportunities for companies in the market.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/sterile-disposable-vacuum-blood-collection-tube-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5321

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
December 16, 2024
Stroke Management Market Trends, AI Integration and Growth
Stroke Management Market Size, Trends, Companies and AI Impact

The global stroke management market was valued at approximately US$ 38.83 billion in 2023 and is projected to reach around US$ 85.5 billion by 2034, with an annual growth rate of 7.44% from 2024 to 2034. This market growth is driven by the critical need for effective stroke management. If a stroke is not promptly treated, it can lead to the continued death of brain cells in the affected area, causing permanent brain damage. As a result, timely and appropriate stroke management is crucial for minimizing these long-term effects.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5374

Market Overview

The stroke management market is experiencing rapid growth, driven by the need for emergency treatment tailored to the type of stroke—ischemic or hemorrhagic. In ischemic strokes, blood vessels in the brain become blocked or narrowed, while in hemorrhagic strokes, bleeding occurs in the brain. Both conditions reduce the amount of oxygen reaching the brain, often due to blood clots or blockages. Immediate treatment is critical to prevent life-threatening consequences and reduce the risk of long-term damage.

Doctors typically conduct blood tests to assess the risk of bleeding or blood clots, measure drug levels (such as those used to treat blood clots), and check for underlying diseases. Stroke remains the leading cause of long-term disability in adults, with approximately 800,000 strokes occurring in the U.S. each year. Early intervention and rehabilitation play a vital role in improving recovery outcomes.

For example, a study published in JAMA Neurology in 2024 found that argatroban, a medication, was linked to improved brain function in ischemic stroke patients who had early brain damage.

Market Trends
- In December 2023, the Ayushman Arogya scheme aimed to enhance stroke prevention by promoting healthy habits and clean drinking water, along with encouraging social interaction at the community level.
- In June 2023, the Government of Maharashtra’s Public Health Department focused on improving stroke care by ensuring 24/7 CT scanning facilities and stroke specialist availability as part of the ANGELS initiative. New stroke centers were also being established.
- In July 2024, the National Institute of Neurological Disorders and Stroke (NINDS) continued to support research aimed at improving stroke prevention, diagnosis, and treatment, while also working on ways to restore blood flow to the brain and minimize damage after a stroke.
- In May 2023, the FDA approved 22 AI/ML-enabled technologies with specific guidelines for the diagnosis and rehabilitation of stroke.
AI Integration

Artificial intelligence (AI) is increasingly being used to enhance stroke management. AI can process clinical data, test results, and medical imaging to offer personalized treatment recommendations. Additionally, AI-powered devices are helping patients improve mobility and function by analyzing their movement patterns. AI is also being used in rehabilitation programs that address speech, language, and vision issues. Furthermore, AI may predict which patients are at risk for depression or cognitive dysfunction after a stroke, contributing to the growth of the stroke management market.

Enhancing Stroke Management through Public Awareness and Efficient EMS Response

Raising public awareness about stroke symptoms and improving emergency medical services (EMS) are key to ensuring that stroke patients receive timely treatment. Emergency physicians play a crucial role in managing hyperacute stroke cases in both outpatient and hospital settings. Regular training for hospital staff is essential to keep them prepared for stroke emergencies.

One of the most effective ways to raise awareness is through healthcare professionals and activists who are well-connected to local communities. Educating the public about stroke warning signs and the importance of seeking immediate medical care can reduce delays in treatment and improve patient outcomes. This, in turn, contributes to the growth of the stroke management market.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/stroke-management-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5374

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
December 16, 2024
Macular Edema and Macular Degeneration Market Trends, Growth and Future Outlook
Macular Edema and Macular Degeneration Market Growth Outlook

The global market for macular edema and macular degeneration was valued at approximately $10.33 billion in 2023 and is projected to reach around $22.51 billion by 2034, growing at a compound annual growth rate (CAGR) of 7.34% from 2024 to 2034. This growth is driven by the increasing availability of various treatment options for these conditions, such as vascular endothelial growth factor (VEGF) therapy, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and surgical interventions.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5375

Market Trends
- Research Advancements: In November 2024, a neonatologist at the University of Oklahoma received a $2.3 million, five-year grant from the National Institutes of Health to research retinopathy of prematurity, an eye disease that affects premature babies and can lead to long-term vision problems, including blindness. This research is expected to play a key role in driving the growth of the macular edema and macular degeneration market.
- Gene Therapy Innovation: Gene therapy for neovascular age-related macular degeneration (nAMD), such as intravitreal anti-VEGF agents, is revolutionizing treatment options. These therapies offer the potential for long-lasting effects, with recent FDA and EMA approvals for gene therapies targeting RPE65-associated retinal dystrophy paving the way for more advanced retinal gene therapy treatments. This is expected to accelerate the development of the macular edema and macular degeneration market.
- Public Awareness Campaigns: The American Academy of Ophthalmology’s EyeSmart public education program continues to promote eye health awareness. By providing essential information about eye diseases, pain, and injuries, the program encourages early diagnosis and treatment, which, in turn, contributes to the growth of the macular edema and macular degeneration markets.
- Assistive Technology: In October 2023, the OrCam MyEye, a wearable device that helps blind individuals with daily tasks using artificial intelligence (AI) and computer vision, was introduced. The device attaches to regular glasses and offers increased independence to users, demonstrating how assistive technology is making a positive impact on those affected by visual impairments, further supporting market growth.
AI Integration
- Deep Learning for Diagnosis and Treatment: AI is becoming increasingly important in managing macular edema and macular degeneration. Deep learning (DL) models are now capable of diagnosing age-related macular degeneration (AMD), predicting short-term hospitalization risks, and forecasting the need for injections in the following two years. These AI models can also adjust anti-VEGF treatment plans with greater accuracy than human specialists, enhancing patient care.
- Predictive Tools for Treatment: Machine learning (ML) models are helping to predict how patients will respond to treatments, which can significantly improve patient compliance. These predictive tools are reducing the uncertainty around treatment outcomes, making it easier for doctors to customize care and for patients to stay on track with their treatment plans.
- Cost Reduction through AI: The integration of AI-driven tools is improving the management of diabetic macular edema (DME) and other retinal diseases. By providing more accurate treatment plans and increasing the efficiency of disease management, these AI tools are helping reduce costs for retinal doctors and patients alike. This cost-saving potential is a major driver of growth in the macular edema and macular degeneration market, making treatments more accessible and affordable for a larger patient population.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/macular-edema-and-macular-degeneration-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5375

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
December 16, 2024
Bone Densitometer Market Key Trends, Growth Drivers and Future Outlook

Bone Densitometer Market Growth, Trends, and Future Outlook

The global bone densitometer market was valued at approximately USD 308.33 million in 2023 and is expected to grow to around USD 466.83 million by 2032. This growth reflects a compound annual growth rate (CAGR) of 4.3% from 2024 to 2032.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5125

Key Highlights of the Bone Densitometer Market Trends and Developments

DXA Dominates the Market Dual-energy X-ray absorptiometry (DXA) emerged as the leading technology in the bone density testing market in 2023, continuing its position as the most preferred method for diagnosing bone health.

Osteoporosis and Osteopenia Lead Applications Osteoporosis and osteopenia diagnoses were the most common applications for bone densitometers, accounting for over 60% of the market share in 2023.

Hospitals and Clinics Drive DXA Use Hospitals and specialty clinics remained the primary locations for conducting DXA scans in 2023, underscoring their central role in assessing bone health.

The Growing Need for Bone Densitometers in Older Adults

As people age, their bones become more fragile, which increases the risk of fractures. This is particularly concerning for older individuals, especially women post-menopause. Bone densitometers play a vital role in monitoring bone health, as they measure bone density to assess strength and detect any potential issues early.

For example, the global elderly population has seen significant growth. In 2021, there were 761 million individuals aged 65 and older, and by 2030, this number is expected to surpass 1 billion. The rising number of older adults worldwide is contributing to a higher incidence of bone-related issues like osteoporosis, further driving the demand for bone densitometers. As these machines become more accurate and accessible, they are increasingly available in hospitals and clinics to help doctors monitor bone health in aging populations.

Early Detection of Osteoporosis: Reducing the Risk of Fractures

The rising number of osteoporosis cases, especially among women after menopause, is another key driver of market growth. According to the International Osteoporosis Foundation, around 200 million women globally are affected by osteoporosis. This condition makes bones weak and prone to fractures. Bone densitometers are essential for detecting osteoporosis early, enabling doctors to recommend treatments to strengthen bones and reduce fracture risks.

For instance, lifestyle habits like smoking, excessive alcohol consumption, and physical inactivity are linked to higher osteoporosis rates, creating a growing need for early detection. Bone densitometers help identify those at risk, allowing for timely intervention with medication, lifestyle changes, or supplements to improve bone health.

Bone Health in Kidney Disease Patients

The increasing prevalence of kidney disease is also contributing to the growing demand for bone densitometers. Kidney diseases, which affect around 37 million adults in the U.S. alone, can disrupt the regulation of essential minerals like calcium, which are vital for bone strength. When the kidneys don’t function properly, it can lead to weakened bones and an increased risk of fractures.

Doctors often use bone densitometers to assess bone health in patients with kidney disease, as these devices help monitor bone density and prevent complications. With kidney diseases becoming more prevalent, particularly due to conditions like diabetes and high blood pressure, the demand for bone densitometers in managing bone health in these patients is rising.

Advancements in DXA Technology

Dual-energy X-ray absorptiometry (DEXA) scans are gaining popularity due to their effectiveness in detecting bone problems early. These scans are a non-invasive way for doctors to check bone density and detect osteoporosis, helping to reduce the risk of fractures.

For example, in February 2022, Aurora Spine partnered with Echolight Medical to promote their radiation-free “Echos portable densitometer,” which assesses bone mineral density (BMD) using advanced software. This collaboration has boosted sales and expanded access to DXA technology, making it more available to healthcare providers and patients.

As people age and the risk of osteoporosis increases, the need for DEXA scans continues to grow. With advancements in technology, DEXA machines are becoming more accurate, accessible, and widespread, allowing doctors to provide better care and prevent bone-related injuries.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/bone-densitometer-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5125

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

December 16, 2024